Enlivex Financial Statements From 2010 to 2025

ENLV Stock  USD 1.15  0.07  5.74%   
Enlivex Therapeutics financial statements provide useful quarterly and yearly information to potential Enlivex Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Enlivex Therapeutics financial statements helps investors assess Enlivex Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Enlivex Therapeutics' valuation are summarized below:
Market Capitalization
26.8 M
Earnings Share
(0.98)
There are over one hundred nineteen available fundamental signals for Enlivex Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should verify Enlivex Therapeutics' prevailing fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to climb to about 50.2 M in 2025, whereas Enterprise Value is likely to drop slightly above 41.9 M in 2025.

Enlivex Therapeutics Total Revenue

2.28 Million

Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 15.3 K, Total Revenue of 0.0 or Research Development of 23.2 M, as well as many indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.82. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Enlivex Therapeutics Correlation against competitors.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Enlivex Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30.6 M33.1 M31.8 M
Pretty Stable
Other Current Liabilities2.4 M4.4 M2.2 M
Slightly volatile
Total Current Liabilities3.6 M5.5 M3.2 M
Slightly volatile
Total Stockholder Equity25.2 M27.1 M27.7 M
Pretty Stable
Accounts Payable1.1 M744.3 K905.8 K
Pretty Stable
Cash888.2 K935 KM
Pretty Stable
Short Term Investments32 M30.5 M20 M
Pretty Stable
Other Current Assets3.8 M7.4 M8.5 M
Slightly volatile
Total Liabilities5.5 M6.1 M4.1 M
Slightly volatile
Intangible Assets350.6 K369 K3.9 M
Slightly volatile
Common Stock2.6 M2.5 M929.2 K
Slightly volatile
Property Plant Equipment18 M17.1 M4.9 M
Slightly volatile
Long Term Debt3.4 M3.6 M4.1 M
Slightly volatile
Good Will19.9 M13.6 M16.3 M
Slightly volatile
Preferred Stock Total Equity10.2 M9.7 M8.1 M
Slightly volatile
Other Liabilities5.1 M4.9 MM
Slightly volatile
Cash And Short Term Investments23 M31.4 M19.1 M
Slightly volatile
Net Receivables250.2 K263.4 K527.5 K
Slightly volatile
Common Stock Total EquityM1.9 M766.8 K
Slightly volatile
Common Stock Shares Outstanding22.4 M21.4 M7.9 M
Slightly volatile
Liabilities And Stockholders Equity31.4 M42.4 M26 M
Slightly volatile
Other Stockholder Equity167.8 M159.8 M66.1 M
Slightly volatile
Total Current Assets28.5 M38.8 M23.6 M
Slightly volatile
Property Plant And Equipment NetMM2.2 M
Slightly volatile
Non Current Assets Total3.2 M3.5 M2.4 M
Slightly volatile
Property Plant And Equipment Gross4.3 M7.6 M3.2 M
Slightly volatile
Capital Surpluse32.3 M33.4 M38.3 M
Slightly volatile
Net Tangible Assets32.8 M65.4 M23.7 M
Slightly volatile
Net Invested Capital36.3 M34.6 M20.3 M
Slightly volatile
Net Working Capital33.3 M31.9 M18.7 M
Slightly volatile
Capital Stock1.8 M2.5 M1.4 M
Slightly volatile
Short and Long Term Debt Total1.5 M1.2 M663.5 K
Slightly volatile
Capital Lease Obligations1.2 M1.2 M385.5 K
Slightly volatile
Non Current Liabilities Other2.9 M4.8 M1.6 M
Slightly volatile
Short Term Debt427.2 K397.9 K242.1 K
Slightly volatile

Enlivex Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Research Development23.2 M22.1 MM
Slightly volatile
Cost Of Revenue713.9 K751.5 KM
Slightly volatile
Selling General Administrative8.1 M5.5 M5.8 M
Pretty Stable
Other Operating Expenses35.5 M33.8 M13.4 M
Slightly volatile
Total Operating Expenses35.5 M33.8 M13.4 M
Slightly volatile
Depreciation And AmortizationM960.2 K367.5 K
Slightly volatile
Selling And Marketing Expenses7.4 MM3.6 M
Slightly volatile
Interest Income1.9 M1.8 M467.5 K
Slightly volatile
Reconciled DepreciationM984.4 K332.6 K
Slightly volatile

Enlivex Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities393.3 K414 K14.1 M
Pretty Stable
Stock Based Compensation1.4 M2.2 M1.2 M
Slightly volatile
End Period Cash Flow1.3 M1.4 M7.3 M
Slightly volatile
Begin Period Cash Flow60.8 M57.9 M14.9 M
Slightly volatile
Sale Purchase Of Stock10.2 M7.5 M16 M
Slightly volatile
DepreciationM960.2 K305.2 K
Slightly volatile
Issuance Of Capital Stock307.8 K324 K8.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio39.0143.8847.8417
Slightly volatile
PTB Ratio1.821.92231
Slightly volatile
Book Value Per Share1.771.8613.8202
Slightly volatile
Stock Based Compensation To Revenue0.230.260.2881
Slightly volatile
Capex To Depreciation0.310.335.5619
Slightly volatile
PB Ratio1.821.92231
Slightly volatile
EV To Sales37.0841.7245.4841
Slightly volatile
Payables Turnover0.50.910.4489
Slightly volatile
Sales General And Administrative To Revenue1.261.421.5517
Slightly volatile
Research And Ddevelopement To Revenue2.142.412.6231
Slightly volatile
Capex To Revenue0.360.40.4391
Slightly volatile
Cash Per Share1.611.6914.694
Slightly volatile
Days Payables Outstanding39541611.7 K
Slightly volatile
Income Quality0.680.730.8039
Slightly volatile
Intangibles To Total Assets0.01860.0210.0229
Slightly volatile
Current Ratio12.246.419.7512
Very volatile
Tangible Book Value Per Share1.771.8613.8173
Slightly volatile
Shareholders Equity Per Share1.771.8613.8202
Slightly volatile
Debt To Equity0.0230.03090.0185
Slightly volatile
Capex Per Share0.01090.01140.0762
Pretty Stable
Graham Net Net1.211.2713.039
Slightly volatile
Revenue Per Share0.140.160.17
Slightly volatile
Interest Debt Per Share0.0960.05070.0588
Slightly volatile
Debt To Assets0.01890.02520.0141
Slightly volatile
Price Book Value Ratio1.821.92231
Slightly volatile
Days Of Payables Outstanding39541611.7 K
Slightly volatile
Ebt Per Ebit0.80.890.9838
Pretty Stable
Company Equity Multiplier1.381.411.3752
Slightly volatile
Total Debt To Capitalization0.02170.02980.0177
Slightly volatile
Debt Equity Ratio0.0230.03090.0185
Slightly volatile
Quick Ratio6.096.419.9477
Very volatile
Net Income Per E B T0.831.231.0513
Pretty Stable
Cash Ratio0.150.13415.4473
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.860.911.0316
Very volatile
Price To Book Ratio1.821.92231
Slightly volatile
Fixed Asset Turnover0.850.961.0441
Slightly volatile
Debt Ratio0.01890.02520.0141
Slightly volatile
Price Sales Ratio39.0143.8847.8417
Slightly volatile
Asset Turnover0.04510.05080.0554
Slightly volatile
Gross Profit Margin0.70.790.8582
Slightly volatile
Price Fair Value1.821.92231
Slightly volatile

Enlivex Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap50.2 M45.1 M55 M
Pretty Stable
Enterprise Value41.9 M45.3 M46.8 M
Pretty Stable

Enlivex Fundamental Market Drivers

Cash And Short Term Investments27.3 M

Enlivex Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
21st of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Enlivex Therapeutics Financial Statements

Enlivex Therapeutics investors use historical fundamental indicators, such as Enlivex Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Enlivex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue751.5 K713.9 K
Stock Based Compensation To Revenue 0.26  0.23 
Sales General And Administrative To Revenue 1.42  1.26 
Research And Ddevelopement To Revenue 2.41  2.14 
Capex To Revenue 0.40  0.36 
Revenue Per Share 0.16  0.14 
Ebit Per Revenue(3.87)(4.06)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.